David J. Katzoff
Known title: Chief Financial OfficerCIK: 0001864317
David J. Katzoff's purchase track record
How the stock did after each of David J. Katzoff's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since September 14, 2022
Stock higher 6 months later
0%
3 months: 0%
Median 6-month return
-65.3%
3 months: -66.6%
Beat the S&P 500
0%
median -87.0% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/21/2025 | ALZN | $5K | -66.6% | -73.6% | +17.6% |
| 9/26/2023 | ALZN | $10K | -68.5% | -65.3% | +21.8% |
| 9/14/2022 | ALZN | $11K | -18.3% | -58.0% | -1.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ALZN | ▲ Buy | Open Market | 5,000 | $5K | 3/21/2025 | View on chart |
| ALZN | ▲ Buy | Open Market | 53,000 | $10K | 9/26/2023 | View on chart |
| ALZN | ▲ Buy | Open Market | 10,000 | $11K | 9/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Alzamend Neuro (ALZN) Receives Analyst Upgrade
Alzamend Neuro received an upgrade to a buy rating from an analyst. This move aligns with the firm's price target of $26.00, which is significantly higher than the stock's 52-week range of $0.84 to $2.68. The upgrade provides a positive signal for the company's outlook, although the stock currently trades near its support level.
Alzamend Neuro (ALZN) Receives Analyst Upgrade. Alzamend Neuro received an upgrade to a buy rating from an analyst. This move aligns with the firm's price target of $26.00, which is significantly higher than the stock's 52-week range of $0.84 to $2.68. The upgrade provides a positive signal for the company's outlook, although the stock currently trades near its support level.